Treatmybrand


a Kainjoo SA Venture
Ch. du Vernay 14a
1196 Gland
+41.21.561.34.96
info@treatmybrand.com

Support


Monday to Friday
8AM to 8PM
support@treatmybrand.com
Back

STAT examines key questions on FDA’s direction after Overton

STAT reports on the main questions facing the FDA following the end of the Overton era. The article outlines concerns about the agency’s next steps and the issues that may shape its future, according to STAT.

For pharma and biotech executives, the FDA’s direction affects drug development timelines, approval strategies and compliance risk. Shifts in regulatory focus could influence investment and R&D planning. Firms should watch for early signs of policy change.

Stat
Stat